What is LivFul?
LivFul is executing a bold and believable plan to reach one billion people daily by 2040 through its “Proof–Pipeline–Platform” model. Having achieved 83% of 2024 objectives, the company entered 2025 with strong momentum, including EPA approval for its repellent enabling U.S. sales, regulatory approval in China, and new preclinical cancer program results. Backed by partnerships with the WHO and Global Fund, LivFul is tackling multi-billion-dollar global health challenges—vector-borne disease, cancer, and rare diseases—through a growing IP portfolio and scalable biotech platform.
“Safe medicines for the world’s underserved populations.”
Competitive Advantages:
EPA and China regulatory approvals establish early global market access.
Dual-impact IP portfolio spanning repellents and oncology provides diversified growth channels.
Partnerships with WHO and Global Fund validate scientific credibility and mission reach.
Three-stage commercialization model (Proof-Pipeline-Platform) provides a clear scaling roadmap.
Redemptive biotech positioning aligns life-saving innovation with Kingdom impact.
HKR LivFul Theme Verse
“Therefore we do not lose heart. Though outwardly we are wasting away, yet inwardly we are being renewed day by day.”